GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zentalis Pharmaceuticals Inc (NAS:ZNTL) » Definitions » Piotroski F-Score

ZNTL (Zentalis Pharmaceuticals) Piotroski F-Score : 5 (As of Mar. 19, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Zentalis Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zentalis Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Zentalis Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

ZNTL' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 2   Max: 6
Current: 5

During the past 6 years, the highest Piotroski F-Score of Zentalis Pharmaceuticals was 6. The lowest was 2. And the median was 2.


Zentalis Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Zentalis Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zentalis Pharmaceuticals Piotroski F-Score Chart

Zentalis Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A 2.00 2.00 2.00 2.00

Zentalis Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 6.00 5.00 5.00

Competitive Comparison of Zentalis Pharmaceuticals's Piotroski F-Score

For the Biotechnology subindustry, Zentalis Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zentalis Pharmaceuticals's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zentalis Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -60.917 + 10.068 + -88.277 + -40.158 = $-179.28 Mil.
Cash Flow from Operations was -40.599 + -51.974 + -35.139 + -44.045 = $-171.76 Mil.
Revenue was 0 + 40.56 + 0 + 0 = $40.56 Mil.
Gross Profit was 0 + 40.56 + 0 + 0 = $40.56 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(585.715 + 551.688 + 557.479 + 491.68 + 450.661) / 5 = $527.4446 Mil.
Total Assets at the begining of this year (Sep23) was $585.72 Mil.
Long-Term Debt & Capital Lease Obligation was $40.46 Mil.
Total Current Assets was $400.27 Mil.
Total Current Liabilities was $54.88 Mil.
Net Income was -54.971 + -63.219 + -112.527 + -55.528 = $-286.25 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(529.193 + 539.31 + 489.342 + 621.444 + 585.715) / 5 = $553.0008 Mil.
Total Assets at the begining of last year (Sep22) was $529.19 Mil.
Long-Term Debt & Capital Lease Obligation was $43.27 Mil.
Total Current Assets was $528.26 Mil.
Total Current Liabilities was $58.92 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zentalis Pharmaceuticals's current Net Income (TTM) was -179.28. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zentalis Pharmaceuticals's current Cash Flow from Operations (TTM) was -171.76. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-179.284/585.715
=-0.30609426

ROA (Last Year)=Net Income/Total Assets (Sep22)
=-286.245/529.193
=-0.54090852

Zentalis Pharmaceuticals's return on assets of this year was -0.30609426. Zentalis Pharmaceuticals's return on assets of last year was -0.54090852. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zentalis Pharmaceuticals's current Net Income (TTM) was -179.28. Zentalis Pharmaceuticals's current Cash Flow from Operations (TTM) was -171.76. ==> -171.76 > -179.28 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=40.457/527.4446
=0.07670379

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=43.266/553.0008
=0.07823858

Zentalis Pharmaceuticals's gearing of this year was 0.07670379. Zentalis Pharmaceuticals's gearing of last year was 0.07823858. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=400.27/54.877
=7.29394828

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=528.264/58.918
=8.96608846

Zentalis Pharmaceuticals's current ratio of this year was 7.29394828. Zentalis Pharmaceuticals's current ratio of last year was 8.96608846. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zentalis Pharmaceuticals's number of shares in issue this year was 71.111. Zentalis Pharmaceuticals's number of shares in issue last year was 70.612. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=40.56/40.56
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Zentalis Pharmaceuticals's gross margin of this year was 1. Zentalis Pharmaceuticals's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=40.56/585.715
=0.0692487

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=0/529.193
=0

Zentalis Pharmaceuticals's asset turnover of this year was 0.0692487. Zentalis Pharmaceuticals's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zentalis Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Zentalis Pharmaceuticals  (NAS:ZNTL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zentalis Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Zentalis Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zentalis Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1359 Broadway, Suite 801, New York, NY, USA, 10018
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Executives
Andrea Paul officer: General Counsel 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jan Skvarka director C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Diana Hausman director C/O ONCOTHYREON INC., 2601 FOURTH AVE, SUITE 500, SEATTLE WA 98121
Melissa B, Epperly officer: Chief Financial Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
David Michael Johnson director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Carrie Brownstein officer: Chief Medical Officer 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Kevin D. Bunker officer: Chief Operating Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Iris Roth officer: Chief Operating Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Anthony Y Sun director, officer: President & CEO C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Alexis Pinto officer: Chief Legal Officer C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Dimitris Voliotis officer: SVP, Clinical Development C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Enoch Kariuki director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901